Trials / Completed
CompletedNCT00309088
FK506 Phase 3 Study: a Study for Steroid Non-resistant Myasthenia Gravis (MG) Patients
FK506 Phase 3 Study: a Double Blind Placebo Controlled Study for Steroid Non-Resistant Myasthenia Gravis Patients
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 80 (actual)
- Sponsor
- Astellas Pharma Inc · Industry
- Sex
- All
- Age
- 16 Years – 64 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of the study is to investigate the efficacy and safety for steroid non-resistant MG patients in a double blind, placebo controlled study.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | tacrolimus | oral |
| DRUG | placebo | oral |
Timeline
- Start date
- 2006-04-01
- Primary completion
- 2008-06-01
- Completion
- 2008-06-01
- First posted
- 2006-03-31
- Last updated
- 2014-08-25
Locations
9 sites across 1 country: Japan
Source: ClinicalTrials.gov record NCT00309088. Inclusion in this directory is not an endorsement.